To investigate the possible utility of targeting the JAK–STAT pathway, two primary SS samples harbouring mutations in JAK1 (SS87 p.Y654F and SS29 pL710V) were subjected to JAK inhibition. Here, SOAT1 is linked to synovial sarcoma.